Protein clumps in the brain have long been associated with Alzheimer’s, but other potential causes of the condition are now ...

But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...